United Therapeutics targets 2026 FDA submission for Tyvaso IPF indication after TETON-2 success
TETON-2 phase 3 data show nebulized treprostinil slows IPF lung decline and cuts clinical worsening risk. Analysis of what the NEJM results mean.
Pharma & Biotech
Pharma & Biotech
JAMA validates nalbuphine ER’s efficacy in IPF chronic cough as Trevi eyes next steps
Trevi’s IPF cough trial results for nalbuphine ER get published in JAMA. Find out what this means for future approvals and respiratory drug development.
Pharma & Biotech
Cereno Scientific’s CS014 shows antithrombotic effect without bleeding risk in new HDAC study
Cereno Scientific has announced the peer-reviewed publication of its next-generation HDAC inhibitor CS014 in the Journal of Thrombosis and Haemostasis, revealing the compound’s ability to significantly reduce thrombosis without increasing bleeding risk. The study marks the first formal disclosure of CS014’s chemical structure and nonclinical pharmacology, positioning the compound as a differentiated HDAC inhibitor with
Pharma & Biotech
Boehringer Ingelheim expands Jascayd label to PPF following pivotal trial success
Boehringer Ingelheim has secured approval from the United States Food and Drug Administration for Jascayd (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults. The decision follows earlier FDA clearance for Jascayd in idiopathic pulmonary fibrosis and now marks the first time a preferential PDE4B inhibitor with dual immunomodulatory and antifibrotic effects has